duragtide + semaglutide + losenatide + tirzepatide + ebenatide

This is a hypothetical or unapproved combination drug consisting of five peptide-based agents—duragtide, semaglutide, losenatide, tirzepatide, and ebenatide. All are glucagon-like peptide 1 (GLP-1) receptor agonists or related incretin mimetics used for glycemic control in type 2 diabetes and/or weight management. Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and obesity; tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and weight loss; the other components (duragtide, losenatide, ebenatide) are not recognized as approved drugs in major regulatory databases as of May 2025. The combination would theoretically act by stimulating insulin secretion in a glucose-dependent manner while suppressing glucagon release and slowing gastric emptying to improve glycemic control and promote weight loss[2][7]. No clinical data exist on the safety or efficacy of this specific five-drug combination.

Other names

duragtidesemaglutidelosenatidetirzepatideebenatide